Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 8/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989107 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL964035 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1309451 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL146037 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL5866373 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL220281 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1286925 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL368074 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2417149 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3231613 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036705-A | PROTAC compound of targeted PI3K alpha and preparation and application thereof | 三亚深海化合物资源中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260041776-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4570837-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119677788-A | Polymer contrast medium | 兴和株式会社 | 2025-03-21 | — | — | CN | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119241502-B | NSD3 degradation agent and preparation method and application thereof | 四川大学华西医院 | 2025-02-28 | — | — | CN | disclosed |
| US-20120101119-A1 | N-substituted indenoisoquinolines and syntheses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-26 | — | — | US | disclosed |
| US-8053443-B2 | N-substituted indenoisoquinolines and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110046113-A1 | AMINE COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7833991-B2 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2009140467-A1 | OXOBENZINDOLIZINOQUINOLINES AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20080318995-A1 | N-Substituted Indenoisoquinolines and Syntheses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | RXFP3, HAX1, MSR1 | TDP1 2333/4885MAOA 3051/4885MAOB 3518/4885 |
| US-20080318995-A1 | N-Substituted Indenoisoquinolines and Syntheses Thereof | GNAQ, NRAS, NPM1 | TDP1 1868/4885MAOA 1700/4885MAOB 937/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | TDP1 3827/4885MAOA 4877/4885MAOB 4869/4885 |
| US-20120101119-A1 | N-substituted indenoisoquinolines and syntheses thereof | GNAQ, NRAS, NPM1 | TDP1 1868/4885MAOA 1700/4885MAOB 937/4885 |
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | TDP1 4143/4885MAOA 504/4885MAOB 405/4885 |
| US-20110046113-A1 | AMINE COMPOUND AND USE THEREOF | NR0B2, NR1D2, NR0B1 | TDP1 4336/4885MAOA 478/4885MAOB 356/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | TDP1 443/4885MAOA 2622/4885MAOB 2338/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | TDP1 3530/4885MAOA 1164/4885MAOB 1515/4885 |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | CXCR4, CXCR6, CCR5 | TDP1 4598/4885MAOA 2977/4885MAOB 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.